In the CYP3A4*22 groups, all variables were balanced in baseline characteristics, except for a significant higher frequency of females (30.3% vs. 22.5%; p = 0.03), prior stroke or TIA (5.3% vs. 2.6%; p = 0.06), more common use of AT-II antagonists (13.2% vs. 9.0%; p = 0.10), and statin use (98.7% vs. 96.5%; p = 0.15). This evidence concerns the gene CYP3A4 and Stroke.